title: Examining IL-33 expression in the cervix of HPV-infected patients: a preliminary study comparing IL-33 levels in different stages of disease and analyzing its potential association with IFN-γ.
abstract: Research has shown the essential role of interleukin-33 (IL-33) in driving protective anti-viral immunity. IFN-γ has been reported to improve IL-33 expression in cultured epithelial cells. The development of cervical intraepithelial neoplasia (CIN) and carcinogenesis was closely related to human papilloma virus (HPV) infection and defective anti-viral immunity. The aim of this study was to investigate IL-33 expression alternation during the disease progress and its association with IFN-γ in HPV-positive patients. IL-33 was detected in endothelial cells and populations of epithelial cells in cervix. Though there was no statistically significant difference of IL-33 levels in cervical lavage and serum among different stages of disease (P > 0.05), the IL-33 protein and mRNA levels in cervical tissues were significantly lower in severe CIN patients than that of mild CIN or no CIN patients (P < 0.05). In addition, IL-33 protein levels were positively correlated with IFN-γ mRNA levels in all groups except cervical cancer (CA) group (r = 0.546, P < 0.01). In vitro, IFN-γ was also found to upregulate IL-33 expression in human epidermal keratinocytes (NHEKs) in a dose-dependent manner. However, CA tissues did not show further reduced IL-33 protein and mRNA levels compared with severe CIN tissues (P > 0.05). IFN-γ mRNA levels were even higher in CA tissues than in severe CIN tissues (P < 0.05). Therefore, in cervical precancerous tissues, IL-33 levels were lower in more severe lesions and that may be related to diminished local IFN-γ.
authors.affiliation: Institute of Laboratory Medicine, Hubei University of Chinese Medicine, Huangjia Lake West Road, Wuhan, 430065, Hubei Province, China, wl_5693@163.com.
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.forename: Hongying
authors.initials: H
authors.lastname: Li
authors.forename: Feng
authors.initials: F
authors.lastname: Liang
authors.forename: Yi
authors.initials: Y
authors.lastname: Hong
authors.forename: Shaowei
authors.initials: S
authors.lastname: Jiang
authors.forename: Ling
authors.initials: L
authors.lastname: Xiao
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics / Q000378:metabolism; D002584:Cervix Uteri / Q000737:chemistry / Q000378:metabolism*; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000032:analysis* / Q000235:genetics / Q000378:metabolism; D000067596:Interleukin-33; D007378:Interleukins / Q000032:analysis* / Q000235:genetics / Q000378:metabolism; D030361:Papillomavirus Infections / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D002583:Uterine Cervical Neoplasms / Q000737:chemistry / Q000378:metabolism*; D002578:Uterine Cervical Dysplasia / Q000737:chemistry / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; C506536:IL33 protein, human; D000067596:Interleukin-33; D007378:Interleukins; D012333:RNA, Messenger; D007371:Interferon-gamma
references.citation: Int Immunol. 2008 Aug;20(8):1019-30
references.pmid: 18550585
references.citation: Gynecol Oncol. 2007 Apr;105(1):228-33
references.pmid: 17289128
references.citation: Curr Opin Immunol. 2014 Jun;28:102-6
references.pmid: 24762410
references.citation: Trends Immunol. 2009 May;30(5):227-33
references.pmid: 19359217
references.citation: Cytokine. 2007 Dec;40(3):216-25
references.pmid: 18023358
references.citation: PLoS One. 2008 Oct 06;3(10):e3331
references.pmid: 18836528
references.citation: Am J Pathol. 2008 Oct;173(4):1229-42
references.pmid: 18787100
references.citation: Cancer Res. 2014 Mar 15;74(6):1789-800
references.pmid: 24448242
references.citation: Gynecol Oncol. 2007 Apr;105(1):157-65
references.pmid: 17229459
references.citation: Int J Cancer. 2009 Mar 15;124(6):1379-83
references.pmid: 19089920
references.citation: Transl Oncol. 2013 Jun 01;6(3):311-8
references.pmid: 23730411
references.citation: J Invest Dermatol. 2012 Nov;132(11):2593-600
references.pmid: 22673732
references.citation: Eur J Immunol. 2011 Nov;41(11):3351-60
references.pmid: 21887788
references.citation: J Dermatol Sci. 2012 Jan;65(1):72-4
references.pmid: 22100205
references.citation: J Rheumatol. 2010 Jan;37(1):18-25
references.pmid: 19918048
references.citation: J Immunol. 2008 Nov 1;181(9):5981-9
references.pmid: 18941187
references.citation: Trends Immunol. 2012 Aug;33(8):389-96
references.pmid: 22609147
references.citation: J Immunol. 2009 Oct 15;183(8):5094-103
references.pmid: 19801525
references.citation: Open Virol J. 2012;6:241-8
references.pmid: 23341859
references.citation: J Clin Neurosci. 2014 Feb;21(2):298-300
references.pmid: 24210798
references.citation: Mediators Inflamm. 2007;2007:24147
references.pmid: 18288269
references.citation: Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):282-7
references.pmid: 17185418
references.citation: J Immunol. 2012 Nov 1;189(9):4331-7
references.pmid: 23028054
references.citation: J Inflamm (Lond). 2011 Aug 26;8(1):22
references.pmid: 21871091
references.citation: Science. 2012 Feb 24;335(6071):984-9
references.pmid: 22323740
references.citation: Vaccine. 2012 Nov 20;30 Suppl 5:F24-33
references.pmid: 23199964
references.citation: J Natl Cancer Inst. 2010 Mar 3;102(5):315-24
references.pmid: 20157096
references.citation: J Pathol. 2001 Sep;195(2):179-85
references.pmid: 11592096
references.citation: Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9021-6
references.pmid: 19439663
references.citation: Immunity. 2005 Nov;23(5):479-90
references.pmid: 16286016